Evelo Biosciences Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Evelo Biosciences stock.
View analyst ratings for Evelo Biosciences or view top-rated stocks.

Wall Street analysts have given Evelo Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Evelo Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Evelo Biosciences is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Evelo Biosciences.

Evelo Biosciences, Inc. (NASDAQ:EVLO) announced its earnings results on Monday, March, 8th. The company reported ($0.62) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.14.
View Evelo Biosciences' earnings history.

Evelo Biosciences' stock was trading at $4.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EVLO stock has increased by 164.5% and is now trading at $11.56.
View which stocks have been most impacted by COVID-19.

5 analysts have issued 1 year target prices for Evelo Biosciences' stock. Their forecasts range from $14.00 to $36.00. On average, they anticipate Evelo Biosciences' share price to reach $20.00 in the next year. This suggests a possible upside of 73.0% from the stock's current price.
View analysts' price targets for Evelo Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Evelo Biosciences include Xencor (XNCR), ALX Oncology (ALXO), Cryoport (CYRX), Arcus Biosciences (RCUS), Prestige Consumer Healthcare (PBH), Dicerna Pharmaceuticals (DRNA), Zentalis Pharmaceuticals (ZNTL), CytoDyn (CYDY), NGM Biopharmaceuticals (NGM), Madrigal Pharmaceuticals (MDGL), Axsome Therapeutics (AXSM), Amarin (AMRN), Revance Therapeutics (RVNC), IGM Biosciences (IGMS) and MacroGenics (MGNX).
View all of EVLO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

(EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVLO stock can currently be purchased for approximately $11.56.

Evelo Biosciences has a market capitalization of $616.55 million. The company earns $-85,470,000.00 in net income (profit) each year or ($2.67) on an earnings per share basis.

Evelo Biosciences employs 90 workers across the globe.

The official website for Evelo Biosciences is www.evelobio.com.

Evelo Biosciences is headquartered at 620 Memorial Drive Suite 500 West, Cambridge MA, 02139.

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at 617-577-0300 or via email at [email protected]